tiprankstipranks
Trending News
More News >
Sinco Pharmaceuticals Holdings Ltd. (HK:6833)
:6833
Hong Kong Market
Advertisement

Sinco Pharmaceuticals Holdings Ltd. (6833) AI Stock Analysis

Compare
0 Followers

Top Page

HK:6833

Sinco Pharmaceuticals Holdings Ltd.

(6833)

Select Model
Select Model
Select Model
Neutral 60 (OpenAI - 4o)
Rating:60Neutral
Price Target:
HK$0.00
▼(-100.00% Downside)
The overall stock score of 60 reflects solid revenue growth and a stable balance sheet, offset by challenges in cash flow management and a bearish technical outlook. The valuation suggests potential undervaluation, but liquidity concerns and lack of momentum weigh on the score.

Sinco Pharmaceuticals Holdings Ltd. (6833) vs. iShares MSCI Hong Kong ETF (EWH)

Sinco Pharmaceuticals Holdings Ltd. Business Overview & Revenue Model

Company DescriptionSinco Pharmaceuticals Holdings Ltd. (6833) is a biopharmaceutical company based in China, primarily engaged in the research, development, manufacturing, and commercialization of innovative pharmaceuticals. The company operates in several therapeutic areas, including oncology, infectious diseases, and chronic diseases, offering a range of prescription drugs and treatment solutions. Sinco is focused on advancing its product portfolio through both in-house development and strategic partnerships, thereby aiming to enhance healthcare outcomes and address unmet medical needs.
How the Company Makes MoneySinco Pharmaceuticals generates revenue through multiple streams, primarily from the sale of its pharmaceutical products, which include generic and proprietary medications. The company's revenue model is largely based on direct sales to hospitals, pharmacies, and healthcare providers. Additionally, Sinco engages in strategic partnerships and collaborations with other pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties based on product sales. The company also invests in research and development to innovate and expand its product offerings, which can lead to new revenue opportunities in the future. Furthermore, regulatory approvals and market entry strategies play a significant role in the company's earnings potential, as successful product launches in key markets can significantly boost revenues.

Sinco Pharmaceuticals Holdings Ltd. Financial Statement Overview

Summary
Sinco Pharmaceuticals Holdings Ltd. shows solid revenue growth and a stable balance sheet, but faces challenges in cash flow management. The recent decline in free cash flow and operating cash flow suggests potential liquidity concerns.
Income Statement
65
Positive
The company has shown consistent revenue growth over the years, with a notable increase from 2020 to 2024. Gross profit margin has remained relatively stable, although there was a decline in net profit margin in the latest year. EBIT and EBITDA margins have shown resilience despite fluctuations in net income.
Balance Sheet
70
Positive
The balance sheet reflects a strong equity position with a consistent increase in stockholders' equity over the years. The debt-to-equity ratio is manageable, indicating a balanced leverage. However, the equity ratio has shown some volatility, which could indicate potential risks.
Cash Flow
55
Neutral
The cash flow statement reveals challenges in maintaining positive free cash flow, with a significant decline in the latest year. Operating cash flow has been inconsistent, impacting the company's ability to generate cash from operations. The free cash flow to net income ratio has been unfavorable recently.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.49B2.82B2.54B2.27B2.02B2.05B
Gross Profit257.43M299.94M323.28M305.87M364.95M273.83M
EBITDA117.26M132.60M126.01M109.01M197.69M152.05M
Net Income42.56M42.05M42.35M69.46M135.08M118.14M
Balance Sheet
Total Assets1.88B2.00B1.89B1.42B1.23B1.25B
Cash, Cash Equivalents and Short-Term Investments232.63M308.32M437.92M329.14M326.05M143.76M
Total Debt227.90M350.54M251.40M192.41M340.95M82.13M
Total Liabilities1.20B1.34B1.26B820.52M857.88M1.09B
Stockholders Equity683.60M662.88M628.05M603.81M374.89M165.34M
Cash Flow
Free Cash Flow-4.48M-268.05M289.16M22.39M282.19M136.93M
Operating Cash Flow21.86M-232.88M353.70M75.08M305.71M137.30M
Investing Cash Flow-44.48M-52.87M-63.63M-119.27M-22.73M-46.84M
Financing Cash Flow-19.05M154.59M-189.73M35.04M-97.11M-169.88M

Sinco Pharmaceuticals Holdings Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.19
Price Trends
50DMA
0.22
Negative
100DMA
0.21
Negative
200DMA
0.21
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
34.59
Neutral
STOCH
14.35
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6833, the sentiment is Negative. The current price of 0.19 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.22, and below the 200-day MA of 0.21, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 34.59 is Neutral, neither overbought nor oversold. The STOCH value of 14.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6833.

Sinco Pharmaceuticals Holdings Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
HK$380.15M8.416.37%1.05%-16.52%-8.87%
53
Neutral
HK$1.50B586.670.45%35.73%-88.89%
52
Neutral
HK$960.00M130.30-16.52%10.61%-1448.48%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
44
Neutral
HK$363.40M-38.24%-31.99%
44
Neutral
HK$320.22M-6.02%-4.13%76.38%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:6833
Sinco Pharmaceuticals Holdings Ltd.
0.19
-0.05
-20.83%
HK:1762
Wanka Online, Inc.
0.88
0.72
450.00%
HK:1993
Asiaray Media Group Ltd.
0.70
-0.20
-22.22%
HK:0205
SEEC Media Group Limited
0.28
0.09
47.37%
HK:2131
Netjoy Holdings Limited
0.46
-0.16
-25.81%
HK:2422
Rego Interactive Co., Ltd.
0.65
0.04
6.56%

Sinco Pharmaceuticals Holdings Ltd. Corporate Events

Sinco Pharmaceuticals Provides Update on Connected Transaction Loan
Aug 15, 2025

Sinco Pharmaceuticals Holdings Ltd. announced a supplemental update regarding a previously issued interest-free loan of HK$5 million to Mr. Huang Xiangbin, a connected person, during the COVID-19 pandemic. The loan, approved by the company’s CFO and CEO, was deemed necessary due to operational instability caused by the pandemic. The company’s board has conducted a thorough review and confirmed that this loan was an isolated incident, with no similar transactions occurring from 2020 to 2024, ensuring transparency and compliance with regulatory standards.

Sinco Pharmaceuticals Schedules Board Meeting to Discuss Interim Results
Aug 15, 2025

Sinco Pharmaceuticals Holdings Limited has announced a board meeting scheduled for August 27, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the recommendation for an interim dividend payment, which could impact shareholder returns and reflect the company’s financial health.

Sinco Pharmaceuticals Announces Connected Transaction Amid Listing Rules Breach
May 30, 2025

Sinco Pharmaceuticals Holdings Ltd. announced a connected transaction involving an interest-free loan of HK$5 million provided by its subsidiary, Hong Kong Prosperous, to Mr. Huang, an executive Director and substantial shareholder. This transaction, which was subject to reporting requirements under the Listing Rules, was initially not announced due to an oversight, resulting in a breach of the rules. The company clarified that the non-compliance was unintentional, arising from a misinterpretation, and was discovered during a regular review of documents. The loan was necessitated by travel restrictions due to the COVID-19 pandemic, which prevented Mr. Huang from completing banking transactions in person.

Sinco Pharmaceuticals Approves New Share Option Scheme at EGM
May 26, 2025

Sinco Pharmaceuticals Holdings Ltd. held an Extraordinary General Meeting on 26 May 2025, where all proposed resolutions were approved by shareholders. The resolutions included the implementation of a new 2025 Share Option Scheme, the authorization to issue new shares, and the termination of the existing share option scheme from 2016. The approval of these resolutions is expected to enhance the company’s operational flexibility and align its share option schemes with current market practices.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 24, 2025